Wells Fargo lowered the price target for the MEI Pharma Inc. (NASDAQ:MEIP) stock from ‘an Overweight’ to ‘an Equal weight’. The rating was released on March 25, 2023, according to finviz. We previously noted in another research note published on March 25, 2023 by Stifel that downgraded the stock from a Buy to a Hold with a price target of $2 for MEIP stock. The research report from Jefferies has downgraded the stock from Buy to Hold, with a price target set at $1. The stock was initiated by Jefferies, who disclosed in a research note on February 03, 2023, to Buy and set the price objective to $4.
1 min read